Human Genome Epidemiology Literature Finder
|
Records 1 - 20 (of 20 Records) |
| Query Trace: Pneumonia and EGFR[original query] |
|---|
| Clinicopathological, Immunohistochemical, and Genetic Features of Primary Lung Adenocarcinoma Occurring in the Setting of Usual Interstitial Pneumonia Pattern. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Aug . Tsuta Koji, Masai Kyohei, Motoi Noriko, Shiraishi Kouya, Furuta Koh, Suzuki Shigeki, Asakura Keisuke, Nakagawa Kazuo, Sakurai Hiroyuki, Watanabe Shun-Ichi, Hiraoka Nobuyoshi, Asamura His |
| Pulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. Medicine 2016 Mar 95 (9): e3008. Hong Dongsheng, Zhang Guobing, Zhang Xingguo, Lian Xinggua |
| FOXP3 rs3761549 polymorphism predicts long-term renal allograft function in patients receiving cyclosporine-based immunosuppressive regimen. Gene 2017 Oct . Xu Qin-Xia, Qiu Xiao-Yan, Jiao Zheng, Zhang Ming, Zhong Ming-Ka |
| FKBP1A rs6041749 polymorphism is associated with allograft function in renal transplant patients. European journal of clinical pharmacology 2018 Sep . Wu Zhuo, Xu Qinxia, Qiu Xiaoyan, Xu Luyang, Jiao Zheng, Zhang Ming, Zhong Mingka |
| Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis. Current medical research and opinion 2019 10 36 (3): 477-482. Cho Byoung Chul, Kim Dong-Wan, Park Keunchil, Lee Jong-Seok, Yoo Seung Soo, Kang Jin Hyoung, Lee Sung Yong, Kim Cheol Hyeon, Jang Seung Hun, Kim Young-Chul, Yoon Hyoung-Kyu, Han Ji-Youn, Kim Sang- |
| The efficacy and safety of osimertinib in treating nonsmall cell lung cancer: A PRISMA-compliant systematic review and meta-analysis. Medicine 2020 Aug 99 (34): e21826. Liu Jing, Li Xuemei, Shao Yinghong, Guo Xiyun, He Jingg |
| Effectiveness of osimertinib in patients with lung adenocarcinoma in clinical practice - the Expanded Drug Access Program in Poland. Advances in respiratory medicine 2020 88 (3): 189-196. Knetki-Wróblewska Magdalena, Kowalski Dariusz M, Czy?ewicz Grzegorz, Bryl Maciej, Wrona Anna, Dziadziuszko Rafa?, Kieszko Robert, Milanowski Janusz, ?winiuch Daria, Ramlau Rodryg, Krzakowski Maci |
| FKBP-CaN-NFAT pathway polymorphisms selected by in silico biological function prediction are associated with tacrolimus efficacy in renal transplant patients. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2020 Dec 105694. Zheng Xinyi, Huai Cong, Xu Qinxia, Xu Luyang, Zhang Ming, Zhong Mingkang, Qiu Xiaoy |
| Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. The Lancet. Respiratory medicine 2021 7 9 (9): 1021-1029. He Jianxing, Su Chunxia, Liang Wenhua, Xu Shidong, Wu Lin, Fu Xiangning, Zhang Xiaodong, Ge Di, Chen Qun, Mao Weimin, Xu Lin, Chen Chun, Hu Bing, Shao Guoguang, Hu Jian, Zhao Jian, Liu Xiaoqing, Liu Zhidong, Wang Zheng, Xiao Zemin, Gong Taiqian, Lin Wen, Li Xingya, Ye Feng, Liu Yang, Ma Haitao, Huang Yunchao, Zhou Jianying, Wang Zhonglin, Fu Junke, Ding Lieming, Mao Li, Zhou Caic |
| Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer. Interactive cardiovascular and thoracic surgery 2021 Oct . Moriya Tetsuji, Hamaji Masatsugu, Yoshizawa Akihiko, Miyata Ryo, Noguchi Misa, Tamari Shigeyuki, Chiba Naohisa, Miyamoto Hideaki, Toyazaki Toshiya, Tanaka Satona, Yamada Yoshito, Yutaka Yojiro, Nakajima Daisuke, Ohsumi Akihiro, Menju Toshi, Date Hiros |
| Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma. BMC cancer 2022 7 22 (1): 762. Sun Meiling, Ji Huaijun, Xu Ning, Jiang Peng, Qu Tao, Li |
| Primary lesion radiotherapy during first-line icotinib treatment in EGFR-mutated NSCLC patients with multiple metastases and no brain metastases: a single-center retrospective study. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 2022 Jul . Deng Rui, Liu Jinkun, Song Tongjun, Xu Tao, Li Yong, Duo Long, Xiang Longchao, Yu Xiongjie, Lei Jinhua, Cao Fengj |
| Deleterious Pulmonary Surfactant System Gene Mutations in Lung Adenocarcinomas Associated With Usual Interstitial Pneumonia. JCO precision oncology 2022 2 2 1-24. Honda Takayuki, Sakashita Hiroyuki, Masai Kyohei, Totsuka Hirohiko, Motoi Noriko, Kobayashi Masashi, Akashi Takumi, Mimaki Sachiyo, Tsuchihara Katsuya, Chiku Suenori, Shiraishi Kouya, Shimada Yoko, Otsuka Ayaka, Kanai Yae, Okubo Kenichi, Watanabe Shun-Ichi, Tsuta Koji, Inase Naohiko, Kohno Takas |
| Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2022 Feb . Shi Yuankai, Zhao Yanqiu, Yang Sheng, Zhou Jianying, Zhang Liangming, Chen Gongyan, Fang Jian, Zhu Bo, Li Xingya, Shu Yongqian, Shi Jianhua, Zheng Rongsheng, Wang Donglin, Yu Huiqing, Huang Jianan, Zhuang Zhixiang, Wu Gang, Zhang Longzhen, Guo Zhongliang, Greco Michael, Li Xiao, Zhang |
| Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. The New England journal of medicine 2023 6 . Masahiro Tsuboi, Roy S Herbst, Thomas John, Terufumi Kato, Margarita Majem, Christian Grohé, Jie Wang, Jonathan W Goldman, Shun Lu, Wu-Chou Su, Filippo de Marinis, Frances A Shepherd, Ki Hyeong Lee, Nhieu Thi Le, Arunee Dechaphunkul, Dariusz Kowalski, Lynne Poole, Ana Bolanos, Yuri Rukazenkov, Yi-Long Wu, |
| Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study. Targeted oncology 2023 6 . Chao-Hua Chiu, Meng-Chih Lin, Yu-Feng Wei, Gee-Chen Chang, Wu-Chou Su, Te-Chun Hsia, Jian Su, Anne Kuei-Fang Wang, Min-Hua Jen, Tarun Puri, Jin-Yuan Sh |
| Efficacy and safety analysis of anlotinib combined with PD-1 inhibitors in advanced non-small cell lung cancer: a retrospective cohort study. Journal of thoracic disease 2023 5 15 (4): 2003-2011. Xuanting Ye, Aimi Huang, Yan Zhou, Yanbin Kuang, Weimin Wang, Aiqin Gu, Ling |
| Safety and Efficacy of Gefitinib Administration After Osimertinib-Induced Interstitial Lung Disease: A Six-Case Series. OncoTargets and therapy 2024 9 17 717-726. Kaoruko Shimbu, Kakeru Hisakane, Naohiro Kadoma, Shunichi Nishima, Kenichiro Atsumi, Masahiro Seike, Takashi Hiro |
| A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the Korean Cancer Study Group (LU17-19). Lung cancer (Amsterdam, Netherlands) 2024 7 194 107870. Yu Jung Kim, Soyeon Kim, Tae Min Kim, Koung Jin Suh, Miso Kim, Se Hyun Kim, Bhumsuk Keam, Dong-Wan Kim, Jong Seok Lee, Dae Seog H |
| Impact of ABCG2 rs2231142(421C>A) Variant on the Clinical Outcomes of Patients With EGFR-mutated Non-small Cell Lung Cancer Treated With Gefitinib: A Comprehensive Meta-analysis. Anticancer research 2024 12 44 (12): 5361-5370. Francisco Cezar Aquino DE Moraes, Maria Eduarda Cavalcanti Souza, Emanuele Rocha DA Silva, Michele Kreuz, Rommel Mario Rodriguez Burba |
- Page last reviewed:Feb 1, 2024
- Content source: